


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

in which:

X is C<sub>1-6</sub>alkyl or OR<sup>6</sup>;

Y is ~~selected from~~ hydrogen, halogen, CN, nitro, SO<sub>2</sub>R<sup>3</sup>, OR<sup>4</sup>, SR<sup>4</sup>, SOR<sup>3</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>, CONR<sup>4</sup>R<sup>5</sup>, NR<sup>4</sup>R<sup>5</sup>, NR<sup>6</sup>SO<sub>2</sub>R<sup>3</sup>, NR<sup>6</sup>CO<sub>2</sub>R<sup>6</sup>, NR<sup>6</sup>COR<sup>3</sup>, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>7</sub>cycloalkyl or C<sub>1-6</sub>alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, OR<sup>6</sup> and NR<sup>6</sup>R<sup>7</sup>, S(O)<sub>n</sub>R<sup>6</sup>; n is 0, 1 or 2;

Z is phenyl optionally substituted by one or more substituents independently selected from hydrogen, halogen, CN, OH, SH, nitro, COR<sup>9</sup>, CO<sub>2</sub>R<sup>6</sup>, SO<sub>2</sub>R<sup>9</sup>, OR<sup>9</sup>, SR<sup>9</sup>, SOR<sup>9</sup>, SO<sub>2</sub>NR<sup>10</sup>R<sup>11</sup>, CONR<sup>10</sup>R<sup>11</sup>, NR<sup>10</sup>R<sup>11</sup>, NHSO<sub>2</sub>R<sup>9</sup>, NR<sup>9</sup>SO<sub>2</sub>R<sup>9</sup>, NR<sup>6</sup>CO<sub>2</sub>R<sup>6</sup>, NHCOR<sup>9</sup>, NR<sup>9</sup>COR<sup>9</sup>, NR<sup>6</sup>CONR<sup>4</sup>R<sup>5</sup>, NR<sup>6</sup>SO<sub>2</sub>NR<sup>4</sup>R<sup>5</sup>, aryl,

C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>1-6</sub>alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, OR<sup>6</sup>, NR<sup>6</sup>R<sup>7</sup>, S(O)<sub>n</sub>R<sup>6</sup>, CONR<sup>6</sup>R<sup>7</sup>, NR<sup>6</sup>COR<sup>7</sup>, SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup> and NR<sup>6</sup>SO<sub>2</sub>R<sup>7</sup>.

R<sup>1</sup> and R<sup>2</sup> independently represent a hydrogen atom, halogen, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or a C<sub>1-6</sub>alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, NR<sup>6</sup>R<sup>7</sup>, OR<sup>6</sup>, S(O)<sub>n</sub>R<sup>6</sup>;

R<sup>3</sup> represents C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>1-6</sub>alkyl which may be optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, OR<sup>6</sup> and NR<sup>6</sup>R<sup>7</sup>, S(O)<sub>n</sub>R<sup>6</sup>, CONR<sup>6</sup>R<sup>7</sup>, NR<sup>6</sup>COR<sup>7</sup>, SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup> and NR<sup>6</sup>SO<sub>2</sub>R<sup>7</sup>;

R<sup>4</sup> and R<sup>5</sup> independently represent hydrogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>1-6</sub>alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, OR<sup>6</sup> and NR<sup>6</sup>R<sup>7</sup>, S(O)<sub>n</sub>R<sup>6</sup>, CONR<sup>6</sup>R<sup>7</sup>, NR<sup>6</sup>COR<sup>7</sup>, SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup> and NR<sup>6</sup>SO<sub>2</sub>R<sup>7</sup>;

R<sup>6</sup> and R<sup>7</sup> independently represents a hydrogen atom or C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>8</sup> is hydrogen, C<sub>1-4</sub> alkyl, -COC<sub>1-4</sub> alkyl, CO<sub>2</sub>C<sub>1-4</sub>alkyl or CONR<sup>6</sup>C<sub>1-4</sub>alkyl;

R<sup>9</sup> represents aryl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl or C<sub>1-6</sub>alkyl, the latter two groups may be optionally substituted by one or more substituents independently selected from halogen, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, aryl, OR<sup>6</sup> and NR<sup>6</sup>R<sup>7</sup>, S(O)<sub>n</sub>R<sup>6</sup>, CONR<sup>6</sup>R<sup>7</sup>, NR<sup>6</sup>COR<sup>7</sup>, SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup> and NR<sup>6</sup>SO<sub>2</sub>R<sup>7</sup>;

$R^{10}$  and  $R^{11}$  independently represent aryl, hydrogen,  $C_3$ - $C_7$  cycloalkyl or  $C_{1-6}$ alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen,  $C_3$ - $C_7$  cycloalkyl, aryl,  $OR^6$  and  $NR^6R^7$ ,  $S(O)_nR^6$ ,  $CONR^6R^7$ ,  $NR^6COR^7$ ,  $SO_2NR^6R^7$  and  $NR^6SO_2R^7$ .

2. (Previously Presented) A compound according to claim 1 in which  $R^1$  and  $R^2$  independently represent a hydrogen atom,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl,  $C_3$ - $C_7$  cycloalkyl or a  $C_{1-6}$ alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen,  $C_3$ - $C_7$  cycloalkyl,  $NR^6R^7$ ,  $OR^6$ ,  $S(O)_nR^6$ .

3. (Previously presented) A compound according to claim 1 in which X is  $C_{1-4}$ alkyl or  $C_{1-4}$ alkoxy.

4. (Cancelled)

5. (Cancelled)

6. (Previously Presented) A compound according to claim 1 in which Z is substituted by one or more substituents independently selected from halogen,  $C_{1-3}$ alkyl, cyano and  $SO_2R^9$ .

7. (Previously presented) A compound according to claim 1 in which  $R^1$  and  $R^2$  are both hydrogen or one is hydrogen and the other is  $C_{1-3}$  alkyl.

8. (Currently Amended) A compound according to claim 1 selected from:

[(5-Methylbiphenyl-2-yl)oxy]acetic acid,

{[5-Ethyl-4'-(methylsulfonyl)biphenyl-2-yl]oxy}acetic acid,

{[4'-(Ethylsulfonyl)-5-methoxybiphenyl-2-yl]oxy}acetic acid,

~~[[4-Chloro-4'-(ethylsulfonyl)-2',5-dimethyl[1,1'-biphenyl]-2-yl]oxy]-acetic acid,~~  
[[4'-(Ethylsulfonyl)-2',5-dimethyl[1,1'-biphenyl]-2-yl]oxy]-acetic acid,  
2-[[3'-Cyano-5-methyl[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,  
2-[[2'-Fluoro-5'-cyano-5-methyl[1,1'-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,  
and pharmaceutically acceptable salts thereof.

Claims 9-11 (Cancelled)

12. (Previously presented) A method for the therapeutic treatment of asthma or rhinitis in a patient suffering from asthma or rhinitis, which comprises administering to the a patient suffering from asthma or rhinitis a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt as defined in claim 1.

13. (Previously presented) A compound according to claim 2 in which X is C<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkoxy.

14. (Cancelled)

15. (Cancelled)

16. (Previously presented) A compound according to claim 2 in which Z substituted by one or more substituents independently selected from halogen, C<sub>1-3</sub>alkyl, cyano and SO<sub>2</sub>R<sup>9</sup>.

17. (Previously presented) A compound according to claim 2 in which R<sup>1</sup> and R<sup>2</sup> are both hydrogen or one is hydrogen and the other is C<sub>1-3</sub> alkyl.

18. (Previously presented) A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent, or carrier.

19. (Previously presented) A method of producing a CRTh2 receptor inhibitory effect in a patient, which comprises administering to the patient an effective amount of a compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof.